Aten Porus Lifesciences
Description: Avammune is developing highly potent non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1) and more
Current immunotherapies such as checkpoint inhibitors target the adaptive immune system. These therapies despite their success are limited by efficacy in “hot tumors” or poor immune memory. Innate immunity modulators can turn “cold tumors” to responsive “hot tumors” and also reduce cancer recurrence by strengthening immunological memory. These modulators can be effectively combined with a variety of therapeutic modalities such as checkpoint inhibitors, chemotherapy, radiotherapy, and oncolotyic viruses.
Various autoimmune and inflammatory diseases are caused by an overactive innate immune system. By specifically targeting these pathways we have the potential to act upstream from where inflammation starts, thereby allowing us to develop safer and more effective drugs for these diseases.
Founder and Chief Executive Officer
Aten Porus Lifesciences